Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lymphocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm

Cancer Family

Lymphocytic Neoplasm

CI-CAN-00000223Explore in graph →

HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items

NCIt: C7065

Overview
Statistics
Survival
Genomics38
Variants & evidence345
Drugs51
Trials12948
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (351)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 351 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia.
· Case Rep Hematol · 2015 · PMID 26600955 · validated civic_curation pubmed
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).
· Leuk Lymphoma · 2017 · PMID 27855558 · validated civic_curation pubmed
The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene.
· Blood · 1989 · PMID 2499362 · validated civic_curation pubmed
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
· Lab Med · 2019 · PMID 30938769 · validated civic_curation pubmed
SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
· Leuk Lymphoma · 2017 · PMID 28278724 · validated civic_curation pubmed
Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation.
· Leukemia · 2008 · PMID 18007576 · validated civic_curation pubmed
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
· Cancer Sci · 2021 · PMID 33492746 · validated civic_curation

Showing 301–325 of 351 publications

← Previous
1
…
12
13
14
15
Next →

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.

· Oncogene · 2002 · PMID 12483530 · validated civic_curation pubmed

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

· Mol Cancer Ther · 2007 · PMID 18089725 · validated civic_curation pubmed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

· Cell · 2011 · PMID 21889194 · validated civic_curation pubmed

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

· PLoS One · 2011 · PMID 21494621 · validated civic_curation pubmed

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

· Haematologica · 2013 · PMID 23585524 · validated civic_curation pubmed

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

· Blood · 2018 · PMID 29880614 · validated civic_curation pubmed

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

· Nat Med · 2016 · PMID 27135738 · validated civic_curation pubmed

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

· Cell Death Differ · 2013 · PMID 23538418 · validated civic_curation pubmed

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

· Proc Natl Acad Sci U S A · 2012 · PMID 23236167 · validated civic_curation pubmed

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

· Cancer Cell · 2012 · PMID 23079656 · validated civic_curation pubmed

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.

· Leukemia · 2014 · PMID 24186003 · validated civic_curation pubmed

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

· Cell Death Differ · 2014 · PMID 24013721 · validated civic_curation pubmed

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

· Mol Cancer Ther · 2010 · PMID 20124459 · validated civic_curation pubmed

Integrated molecular analysis of adult T cell leukemia/lymphoma.

· Nat Genet · 2015 · PMID 26437031 · validated civic_curation pubmed

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.

· Blood · 2018 · PMID 29434033 · validated civic_curation pubmed

Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.

· Leuk Res · 2014 · PMID 24367893 · validated civic_curation pubmed

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

· Nat Commun · 2019 · PMID 31160589 · validated civic_curation pubmed

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

· Am J Cancer Res · 2016 · PMID 27904766 · validated civic_curation pubmed